Dr Sara Lonardi is Chief of the Oncology 1 Unit of Veneto Institute of Oncology (IOV) – IRCCS. She obtained her Medical Degree in 2000 and her Oncology specialization in 2004, both from the University of Padova. She has been actively interested in the care of gastrointestinal cancer patients since 1998, and in 2013 became chief of the GI Cancer Unit, being involved in several international and national clinical trials as Principal Investigator. She was also Chief of Phase I Clinical Trial Unit at IOV-IRCCS and pro tempore Chief of the Oncology 3 Unit at IOV-IRCCS. She has published more than 200 scientific articles in peer-reviewed journals dealing with gastrointestinal cancers clinical and translational research. She is an active member of Associazione Italiana di Oncologia Medica-AIOM, European Society of Medical Oncology-ESMO and American Society of Medical Oncology-ASCO, and member of the Steering Committee of the ACCENT DataBase.

Amgen, Astellas, Astra Zeneca, Bayer, Bristol-Myers Squibb, Daiichi-Sankyo, GSK, Incyte, Lilly, Merck Serono, MSD, Pierre-Fabre, Roche, Servier, Takeda, Rottapharm Biotech, Beigene, Helion, Fosum Pharma, Nimbus Therapeutics